nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobunolol—Diabetes mellitus—Rosuvastatin—atherosclerosis	0.0225	0.0259	CcSEcCtD
Levobunolol—Diabetes mellitus—Simvastatin—atherosclerosis	0.0178	0.0205	CcSEcCtD
Levobunolol—Diabetes mellitus—Niacin—atherosclerosis	0.0163	0.0188	CcSEcCtD
Levobunolol—Depression—Rosuvastatin—atherosclerosis	0.015	0.0173	CcSEcCtD
Levobunolol—Diplopia—Pravastatin—atherosclerosis	0.014	0.0161	CcSEcCtD
Levobunolol—Erectile dysfunction—Lovastatin—atherosclerosis	0.0132	0.0152	CcSEcCtD
Levobunolol—Erectile dysfunction—Ezetimibe—atherosclerosis	0.0129	0.0149	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.0126	0.0146	CcSEcCtD
Levobunolol—Erectile dysfunction—Simvastatin—atherosclerosis	0.0123	0.0142	CcSEcCtD
Levobunolol—Arrhythmia—Rosuvastatin—atherosclerosis	0.0121	0.0139	CcSEcCtD
Levobunolol—Depression—Simvastatin—atherosclerosis	0.0119	0.0137	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.0118	0.0136	CcSEcCtD
Levobunolol—Erectile dysfunction—Niacin—atherosclerosis	0.0113	0.013	CcSEcCtD
Levobunolol—Erectile dysfunction—Pravastatin—atherosclerosis	0.0111	0.0128	CcSEcCtD
Levobunolol—Erythema multiforme—Lovastatin—atherosclerosis	0.0108	0.0125	CcSEcCtD
Levobunolol—Depression—Pravastatin—atherosclerosis	0.0108	0.0124	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.0107	0.0123	CcSEcCtD
Levobunolol—Erythema multiforme—Ezetimibe—atherosclerosis	0.0106	0.0122	CcSEcCtD
Levobunolol—Erythema multiforme—Simvastatin—atherosclerosis	0.0101	0.0117	CcSEcCtD
Levobunolol—Alopecia—Lovastatin—atherosclerosis	0.0101	0.0117	CcSEcCtD
Levobunolol—Alopecia—Ezetimibe—atherosclerosis	0.00993	0.0114	CcSEcCtD
Levobunolol—Confusional state—Rosuvastatin—atherosclerosis	0.00968	0.0112	CcSEcCtD
Levobunolol—Visual impairment—Niacin—atherosclerosis	0.00948	0.0109	CcSEcCtD
Levobunolol—Alopecia—Simvastatin—atherosclerosis	0.00947	0.0109	CcSEcCtD
Levobunolol—Visual impairment—Pravastatin—atherosclerosis	0.00933	0.0108	CcSEcCtD
Levobunolol—Erythema multiforme—Pravastatin—atherosclerosis	0.00916	0.0106	CcSEcCtD
Levobunolol—Arrhythmia—Niacin—atherosclerosis	0.00879	0.0101	CcSEcCtD
Levobunolol—Alopecia—Niacin—atherosclerosis	0.00869	0.01	CcSEcCtD
Levobunolol—Arrhythmia—Pravastatin—atherosclerosis	0.00865	0.00997	CcSEcCtD
Levobunolol—Palpitations—Ezetimibe—atherosclerosis	0.00864	0.00996	CcSEcCtD
Levobunolol—Paraesthesia—Rosuvastatin—atherosclerosis	0.00862	0.00994	CcSEcCtD
Levobunolol—Alopecia—Pravastatin—atherosclerosis	0.00856	0.00987	CcSEcCtD
Levobunolol—Chest pain—Lovastatin—atherosclerosis	0.00849	0.00978	CcSEcCtD
Levobunolol—Chest pain—Ezetimibe—atherosclerosis	0.00832	0.0096	CcSEcCtD
Levobunolol—Pain—Rosuvastatin—atherosclerosis	0.00821	0.00946	CcSEcCtD
Levobunolol—Confusional state—Lovastatin—atherosclerosis	0.0082	0.00946	CcSEcCtD
Levobunolol—Confusional state—Ezetimibe—atherosclerosis	0.00805	0.00928	CcSEcCtD
Levobunolol—Chest pain—Simvastatin—atherosclerosis	0.00794	0.00915	CcSEcCtD
Levobunolol—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00791	0.00912	CcSEcCtD
Levobunolol—Syncope—Niacin—atherosclerosis	0.00768	0.00885	CcSEcCtD
Levobunolol—Confusional state—Simvastatin—atherosclerosis	0.00767	0.00885	CcSEcCtD
Levobunolol—Urticaria—Rosuvastatin—atherosclerosis	0.00763	0.00879	CcSEcCtD
Levobunolol—Palpitations—Niacin—atherosclerosis	0.00757	0.00872	CcSEcCtD
Levobunolol—Loss of consciousness—Niacin—atherosclerosis	0.00753	0.00868	CcSEcCtD
Levobunolol—Paraesthesia—Lovastatin—atherosclerosis	0.00731	0.00842	CcSEcCtD
Levobunolol—Dyspnoea—Lovastatin—atherosclerosis	0.00725	0.00836	CcSEcCtD
Levobunolol—Chest pain—Pravastatin—atherosclerosis	0.00718	0.00827	CcSEcCtD
Levobunolol—Paraesthesia—Ezetimibe—atherosclerosis	0.00717	0.00826	CcSEcCtD
Levobunolol—Dyspnoea—Ezetimibe—atherosclerosis	0.00711	0.0082	CcSEcCtD
Levobunolol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00707	0.00815	CcSEcCtD
Levobunolol—Pain—Lovastatin—atherosclerosis	0.00696	0.00802	CcSEcCtD
Levobunolol—Confusional state—Pravastatin—atherosclerosis	0.00694	0.008	CcSEcCtD
Levobunolol—Asthenia—Rosuvastatin—atherosclerosis	0.00689	0.00794	CcSEcCtD
Levobunolol—Shock—Niacin—atherosclerosis	0.00687	0.00793	CcSEcCtD
Levobunolol—Paraesthesia—Simvastatin—atherosclerosis	0.00683	0.00788	CcSEcCtD
Levobunolol—Pain—Ezetimibe—atherosclerosis	0.00682	0.00787	CcSEcCtD
Levobunolol—Pruritus—Rosuvastatin—atherosclerosis	0.00679	0.00783	CcSEcCtD
Levobunolol—Dyspnoea—Simvastatin—atherosclerosis	0.00678	0.00782	CcSEcCtD
Levobunolol—Feeling abnormal—Lovastatin—atherosclerosis	0.0067	0.00773	CcSEcCtD
Levobunolol—Feeling abnormal—Ezetimibe—atherosclerosis	0.00658	0.00758	CcSEcCtD
Levobunolol—Diarrhoea—Rosuvastatin—atherosclerosis	0.00657	0.00757	CcSEcCtD
Levobunolol—Hypotension—Niacin—atherosclerosis	0.00653	0.00753	CcSEcCtD
Levobunolol—Pain—Simvastatin—atherosclerosis	0.00651	0.0075	CcSEcCtD
Levobunolol—Urticaria—Lovastatin—atherosclerosis	0.00646	0.00745	CcSEcCtD
Levobunolol—Dizziness—Rosuvastatin—atherosclerosis	0.00635	0.00732	CcSEcCtD
Levobunolol—Urticaria—Ezetimibe—atherosclerosis	0.00634	0.00731	CcSEcCtD
Levobunolol—Paraesthesia—Niacin—atherosclerosis	0.00627	0.00723	CcSEcCtD
Levobunolol—Feeling abnormal—Simvastatin—atherosclerosis	0.00627	0.00723	CcSEcCtD
Levobunolol—Dyspnoea—Niacin—atherosclerosis	0.00623	0.00718	CcSEcCtD
Levobunolol—Paraesthesia—Pravastatin—atherosclerosis	0.00618	0.00712	CcSEcCtD
Levobunolol—Dyspnoea—Pravastatin—atherosclerosis	0.00613	0.00707	CcSEcCtD
Levobunolol—Urticaria—Simvastatin—atherosclerosis	0.00605	0.00697	CcSEcCtD
Levobunolol—Headache—Rosuvastatin—atherosclerosis	0.00601	0.00693	CcSEcCtD
Levobunolol—Hypersensitivity—Lovastatin—atherosclerosis	0.00599	0.00691	CcSEcCtD
Levobunolol—Pain—Niacin—atherosclerosis	0.00598	0.00689	CcSEcCtD
Levobunolol—Pain—Pravastatin—atherosclerosis	0.00588	0.00678	CcSEcCtD
Levobunolol—Hypersensitivity—Ezetimibe—atherosclerosis	0.00588	0.00678	CcSEcCtD
Levobunolol—Asthenia—Lovastatin—atherosclerosis	0.00584	0.00673	CcSEcCtD
Levobunolol—Pruritus—Lovastatin—atherosclerosis	0.00576	0.00664	CcSEcCtD
Levobunolol—Asthenia—Ezetimibe—atherosclerosis	0.00573	0.0066	CcSEcCtD
Levobunolol—Nausea—Rosuvastatin—atherosclerosis	0.0057	0.00657	CcSEcCtD
Levobunolol—Feeling abnormal—Pravastatin—atherosclerosis	0.00567	0.00654	CcSEcCtD
Levobunolol—Pruritus—Ezetimibe—atherosclerosis	0.00565	0.00651	CcSEcCtD
Levobunolol—Hypersensitivity—Simvastatin—atherosclerosis	0.00561	0.00646	CcSEcCtD
Levobunolol—Diarrhoea—Lovastatin—atherosclerosis	0.00557	0.00642	CcSEcCtD
Levobunolol—Urticaria—Niacin—atherosclerosis	0.00555	0.0064	CcSEcCtD
Levobunolol—Urticaria—Pravastatin—atherosclerosis	0.00547	0.0063	CcSEcCtD
Levobunolol—Asthenia—Simvastatin—atherosclerosis	0.00546	0.00629	CcSEcCtD
Levobunolol—Diarrhoea—Ezetimibe—atherosclerosis	0.00546	0.00629	CcSEcCtD
Levobunolol—Pruritus—Simvastatin—atherosclerosis	0.00538	0.00621	CcSEcCtD
Levobunolol—Dizziness—Lovastatin—atherosclerosis	0.00538	0.0062	CcSEcCtD
Levobunolol—Dizziness—Ezetimibe—atherosclerosis	0.00528	0.00608	CcSEcCtD
Levobunolol—Diarrhoea—Simvastatin—atherosclerosis	0.00521	0.006	CcSEcCtD
Levobunolol—Hypersensitivity—Niacin—atherosclerosis	0.00515	0.00594	CcSEcCtD
Levobunolol—Headache—Lovastatin—atherosclerosis	0.0051	0.00588	CcSEcCtD
Levobunolol—Hypersensitivity—Pravastatin—atherosclerosis	0.00507	0.00584	CcSEcCtD
Levobunolol—Dizziness—Simvastatin—atherosclerosis	0.00503	0.0058	CcSEcCtD
Levobunolol—Asthenia—Niacin—atherosclerosis	0.00501	0.00578	CcSEcCtD
Levobunolol—Headache—Ezetimibe—atherosclerosis	0.005	0.00576	CcSEcCtD
Levobunolol—Pruritus—Niacin—atherosclerosis	0.00494	0.0057	CcSEcCtD
Levobunolol—Asthenia—Pravastatin—atherosclerosis	0.00494	0.00569	CcSEcCtD
Levobunolol—Pruritus—Pravastatin—atherosclerosis	0.00487	0.00561	CcSEcCtD
Levobunolol—Nausea—Lovastatin—atherosclerosis	0.00483	0.00557	CcSEcCtD
Levobunolol—Diarrhoea—Niacin—atherosclerosis	0.00478	0.00551	CcSEcCtD
Levobunolol—Headache—Simvastatin—atherosclerosis	0.00477	0.0055	CcSEcCtD
Levobunolol—Nausea—Ezetimibe—atherosclerosis	0.00474	0.00546	CcSEcCtD
Levobunolol—Diarrhoea—Pravastatin—atherosclerosis	0.00471	0.00543	CcSEcCtD
Levobunolol—Dizziness—Niacin—atherosclerosis	0.00462	0.00533	CcSEcCtD
Levobunolol—Dizziness—Pravastatin—atherosclerosis	0.00455	0.00524	CcSEcCtD
Levobunolol—Nausea—Simvastatin—atherosclerosis	0.00452	0.00521	CcSEcCtD
Levobunolol—Headache—Niacin—atherosclerosis	0.00438	0.00505	CcSEcCtD
Levobunolol—Headache—Pravastatin—atherosclerosis	0.00431	0.00497	CcSEcCtD
Levobunolol—Nausea—Niacin—atherosclerosis	0.00415	0.00478	CcSEcCtD
Levobunolol—Nausea—Pravastatin—atherosclerosis	0.00409	0.00471	CcSEcCtD
Levobunolol—ADRB1—GPCR ligand binding—CX3CL1—atherosclerosis	0.00059	0.00445	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CX3CR1—atherosclerosis	0.000588	0.00444	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CASR—atherosclerosis	0.000588	0.00444	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CX3CL1—atherosclerosis	0.000577	0.00435	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.000571	0.00431	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.000571	0.00431	CbGpPWpGaD
Levobunolol—ADRB1—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.000567	0.00427	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CNR2—atherosclerosis	0.000559	0.00422	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.000559	0.00421	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.000559	0.00421	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000557	0.0042	CbGpPWpGaD
Levobunolol—ADRB2—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.000554	0.00418	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—HRH1—atherosclerosis	0.00055	0.00415	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CNR2—atherosclerosis	0.000547	0.00413	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000544	0.00411	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—HRH1—atherosclerosis	0.000538	0.00406	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—HRH1—atherosclerosis	0.0005	0.00377	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—HRH1—atherosclerosis	0.000489	0.00369	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000488	0.00368	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000486	0.00366	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CCL3—atherosclerosis	0.000481	0.00363	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000478	0.0036	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000475	0.00358	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CCL3—atherosclerosis	0.00047	0.00355	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—EDNRA—atherosclerosis	0.000435	0.00328	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CCR2—atherosclerosis	0.000435	0.00328	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—EDNRA—atherosclerosis	0.000425	0.00321	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CCR2—atherosclerosis	0.000425	0.00321	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—GHRL—atherosclerosis	0.000424	0.0032	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—GHRL—atherosclerosis	0.000415	0.00313	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000412	0.0031	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000408	0.00308	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000403	0.00304	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.0004	0.00301	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—KNG1—atherosclerosis	0.000372	0.00281	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—AGTR1—atherosclerosis	0.00037	0.00279	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—KNG1—atherosclerosis	0.000364	0.00274	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—AGTR1—atherosclerosis	0.000362	0.00273	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCL4—atherosclerosis	0.000361	0.00272	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—UTS2—atherosclerosis	0.000355	0.00267	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCL4—atherosclerosis	0.000353	0.00267	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—UTS2—atherosclerosis	0.000347	0.00262	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000342	0.00258	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CASR—atherosclerosis	0.00034	0.00256	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000334	0.00252	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CASR—atherosclerosis	0.000333	0.00251	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—UTS2—atherosclerosis	0.000322	0.00243	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CNR2—atherosclerosis	0.000316	0.00238	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000316	0.00238	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—UTS2—atherosclerosis	0.000315	0.00238	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—EDN1—atherosclerosis	0.000313	0.00236	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CCL5—atherosclerosis	0.000311	0.00235	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CNR2—atherosclerosis	0.000309	0.00233	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000309	0.00233	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CX3CR1—atherosclerosis	0.000309	0.00233	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CASR—atherosclerosis	0.000309	0.00233	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—EDN1—atherosclerosis	0.000307	0.00231	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CCL5—atherosclerosis	0.000304	0.00229	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CX3CL1—atherosclerosis	0.000303	0.00228	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CX3CR1—atherosclerosis	0.000302	0.00228	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CASR—atherosclerosis	0.000302	0.00228	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CX3CL1—atherosclerosis	0.000296	0.00223	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HRH1—atherosclerosis	0.000295	0.00223	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HRH1—atherosclerosis	0.000289	0.00218	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CNR2—atherosclerosis	0.000287	0.00216	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000281	0.00212	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CNR2—atherosclerosis	0.000281	0.00212	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000275	0.00208	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—AGT—atherosclerosis	0.00026	0.00196	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—AGT—atherosclerosis	0.000255	0.00192	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCL3—atherosclerosis	0.000247	0.00186	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—EDNRA—atherosclerosis	0.000246	0.00185	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CCR2—atherosclerosis	0.000246	0.00185	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCL3—atherosclerosis	0.000241	0.00182	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—F2—atherosclerosis	0.00024	0.00181	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—EDNRA—atherosclerosis	0.00024	0.00181	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CCR2—atherosclerosis	0.00024	0.00181	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—GHRL—atherosclerosis	0.00024	0.00181	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—F2—atherosclerosis	0.000235	0.00177	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—GHRL—atherosclerosis	0.000234	0.00177	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APOA4—atherosclerosis	0.000232	0.00175	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APOA4—atherosclerosis	0.000227	0.00171	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—EDNRA—atherosclerosis	0.000223	0.00168	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCR2—atherosclerosis	0.000223	0.00168	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000222	0.00168	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—EDNRA—atherosclerosis	0.000218	0.00165	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCR2—atherosclerosis	0.000218	0.00165	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000218	0.00164	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—GHRL—atherosclerosis	0.000217	0.00164	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CCL2—atherosclerosis	0.000214	0.00162	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCL4—atherosclerosis	0.000213	0.00161	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—GHRL—atherosclerosis	0.000213	0.0016	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—KNG1—atherosclerosis	0.00021	0.00159	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CCL2—atherosclerosis	0.00021	0.00158	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AGTR1—atherosclerosis	0.000209	0.00158	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCL4—atherosclerosis	0.000209	0.00157	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—KNG1—atherosclerosis	0.000206	0.00155	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AGTR1—atherosclerosis	0.000204	0.00154	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APOA2—atherosclerosis	0.000199	0.0015	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APOA2—atherosclerosis	0.000195	0.00147	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—KNG1—atherosclerosis	0.000191	0.00144	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—UTS2—atherosclerosis	0.00019	0.00143	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AGTR1—atherosclerosis	0.00019	0.00143	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—KNG1—atherosclerosis	0.000187	0.00141	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—UTS2—atherosclerosis	0.000186	0.0014	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AGTR1—atherosclerosis	0.000186	0.0014	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CX3CR1—atherosclerosis	0.000182	0.00138	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CASR—atherosclerosis	0.000182	0.00138	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CX3CL1—atherosclerosis	0.000179	0.00135	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CX3CR1—atherosclerosis	0.000178	0.00135	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CASR—atherosclerosis	0.000178	0.00135	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—EDN1—atherosclerosis	0.000177	0.00134	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CCL5—atherosclerosis	0.000176	0.00133	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CX3CL1—atherosclerosis	0.000175	0.00132	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—EDN1—atherosclerosis	0.000173	0.00131	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CCL5—atherosclerosis	0.000172	0.0013	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CNR2—atherosclerosis	0.00017	0.00128	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CXCL8—atherosclerosis	0.000169	0.00128	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MMP3—atherosclerosis	0.000169	0.00128	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PRKCG—atherosclerosis	0.000167	0.00126	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CNR2—atherosclerosis	0.000166	0.00125	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CXCL8—atherosclerosis	0.000166	0.00125	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MMP3—atherosclerosis	0.000165	0.00125	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PRKCG—atherosclerosis	0.000163	0.00123	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—EDN1—atherosclerosis	0.000161	0.00121	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCL5—atherosclerosis	0.00016	0.0012	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—EDN1—atherosclerosis	0.000157	0.00119	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCL5—atherosclerosis	0.000156	0.00118	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PRKCG—atherosclerosis	0.000152	0.00114	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VWF—atherosclerosis	0.000151	0.00114	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APOC3—atherosclerosis	0.00015	0.00113	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LDLR—atherosclerosis	0.000149	0.00113	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PRKCG—atherosclerosis	0.000148	0.00112	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VWF—atherosclerosis	0.000148	0.00111	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AGT—atherosclerosis	0.000147	0.00111	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APOC3—atherosclerosis	0.000147	0.00111	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LDLR—atherosclerosis	0.000146	0.0011	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCL3—atherosclerosis	0.000146	0.0011	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AGT—atherosclerosis	0.000144	0.00108	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCL3—atherosclerosis	0.000143	0.00108	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NCF1—atherosclerosis	0.00014	0.00105	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NCF1—atherosclerosis	0.000137	0.00103	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—F2—atherosclerosis	0.000136	0.00102	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AGT—atherosclerosis	0.000134	0.00101	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—F2—atherosclerosis	0.000133	0.001	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCR2—atherosclerosis	0.000132	0.000994	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EDNRA—atherosclerosis	0.000132	0.000994	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CYBA—atherosclerosis	0.000131	0.00099	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AGT—atherosclerosis	0.000131	0.000985	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CG—atherosclerosis	0.00013	0.000981	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCR2—atherosclerosis	0.000129	0.000973	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EDNRA—atherosclerosis	0.000129	0.000973	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PLAT—atherosclerosis	0.000128	0.000969	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PARP1—atherosclerosis	0.000128	0.000969	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GHRL—atherosclerosis	0.000128	0.000969	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CYBA—atherosclerosis	0.000128	0.000968	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000127	0.000959	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PLAT—atherosclerosis	0.000126	0.000948	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PARP1—atherosclerosis	0.000126	0.000948	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GHRL—atherosclerosis	0.000126	0.000948	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—F2—atherosclerosis	0.000123	0.000931	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—F2—atherosclerosis	0.000121	0.00091	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CG—atherosclerosis	0.000118	0.000891	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CG—atherosclerosis	0.000116	0.000871	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KNG1—atherosclerosis	0.000113	0.000851	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AGTR1—atherosclerosis	0.000112	0.000845	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KNG1—atherosclerosis	0.00011	0.000832	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCL2—atherosclerosis	0.00011	0.000829	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AGTR1—atherosclerosis	0.00011	0.000827	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PLG—atherosclerosis	0.000109	0.000824	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCL2—atherosclerosis	0.000108	0.000811	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PLG—atherosclerosis	0.000107	0.000806	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SOCS3—atherosclerosis	0.000103	0.00078	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SOCS3—atherosclerosis	0.000101	0.000763	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MMP3—atherosclerosis	9.99e-05	0.000754	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IGF2—atherosclerosis	9.95e-05	0.00075	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MMP3—atherosclerosis	9.77e-05	0.000737	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IGF2—atherosclerosis	9.73e-05	0.000734	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APOB—atherosclerosis	9.66e-05	0.000728	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CXCL8—atherosclerosis	9.57e-05	0.000722	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EDN1—atherosclerosis	9.5e-05	0.000717	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APOB—atherosclerosis	9.45e-05	0.000712	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCL5—atherosclerosis	9.43e-05	0.000711	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CXCL8—atherosclerosis	9.37e-05	0.000706	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EDN1—atherosclerosis	9.3e-05	0.000701	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCL5—atherosclerosis	9.22e-05	0.000696	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LPL—atherosclerosis	9.22e-05	0.000695	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LPL—atherosclerosis	9.02e-05	0.00068	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRKCG—atherosclerosis	8.97e-05	0.000676	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRKCG—atherosclerosis	8.77e-05	0.000661	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SPP1—atherosclerosis	8.73e-05	0.000659	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CXCL8—atherosclerosis	8.69e-05	0.000656	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SPP1—atherosclerosis	8.54e-05	0.000644	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CXCL8—atherosclerosis	8.51e-05	0.000641	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDGFB—atherosclerosis	8.08e-05	0.000609	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDGFB—atherosclerosis	7.9e-05	0.000596	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AGT—atherosclerosis	7.89e-05	0.000595	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LEP—atherosclerosis	7.73e-05	0.000583	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APOE—atherosclerosis	7.73e-05	0.000583	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AGT—atherosclerosis	7.72e-05	0.000582	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CAV1—atherosclerosis	7.66e-05	0.000578	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APOA1—atherosclerosis	7.64e-05	0.000576	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APOE—atherosclerosis	7.56e-05	0.00057	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LEP—atherosclerosis	7.56e-05	0.00057	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CAV1—atherosclerosis	7.49e-05	0.000565	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APOA1—atherosclerosis	7.47e-05	0.000564	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ESR1—atherosclerosis	7.38e-05	0.000557	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—F2—atherosclerosis	7.29e-05	0.00055	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ESR1—atherosclerosis	7.22e-05	0.000544	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—F2—atherosclerosis	7.13e-05	0.000538	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CG—atherosclerosis	6.98e-05	0.000526	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	6.82e-05	0.000515	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAPK3—atherosclerosis	6.68e-05	0.000504	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—INS—atherosclerosis	6.6e-05	0.000498	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	6.53e-05	0.000493	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCL2—atherosclerosis	6.5e-05	0.00049	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—INS—atherosclerosis	6.46e-05	0.000487	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IGF1—atherosclerosis	6.39e-05	0.000482	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCL2—atherosclerosis	6.36e-05	0.000479	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IGF1—atherosclerosis	6.25e-05	0.000471	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SERPINE1—atherosclerosis	6.07e-05	0.000457	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	5.93e-05	0.000447	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NOS3—atherosclerosis	5.79e-05	0.000437	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NOS3—atherosclerosis	5.66e-05	0.000427	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	5.14e-05	0.000387	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	5.02e-05	0.000379	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	4.96e-05	0.000374	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL6—atherosclerosis	4.88e-05	0.000368	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	4.85e-05	0.000366	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL6—atherosclerosis	4.78e-05	0.00036	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MMP9—atherosclerosis	4.65e-05	0.00035	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	4.6e-05	0.000347	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MMP9—atherosclerosis	4.54e-05	0.000343	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	4.52e-05	0.000341	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	4.51e-05	0.00034	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	4.5e-05	0.000339	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	4.42e-05	0.000333	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	4.41e-05	0.000332	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	4.17e-05	0.000315	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STAT3—atherosclerosis	4.13e-05	0.000312	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	4.08e-05	0.000308	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT3—atherosclerosis	4.04e-05	0.000305	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	3.95e-05	0.000298	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	3.86e-05	0.000291	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	3.83e-05	0.000289	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	3.75e-05	0.000282	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL6—atherosclerosis	2.89e-05	0.000218	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL6—atherosclerosis	2.82e-05	0.000213	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AKT1—atherosclerosis	2.66e-05	0.000201	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AKT1—atherosclerosis	2.6e-05	0.000196	CbGpPWpGaD
